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ABSTRACT Genomic and darwinian medicine deal 
with the application of hereditary and evolutionary 
principles for the understanding of health and di-
sease. The progress in molecular and bioinformatic 
knowledge is making possible through a holistic 
approach to biological phenomena and one aspect 
of it, host-pathogen coevolution, is discussed with 
examples of research performed by our group. The 
search for the etiology of genetic diseases can focus 
on simple traits with mendelian inheritance or in 
more complex multifactorial characteristics, as well 
as in nuclear or mitochondrial DNA genes. Also im-
portant is the investigation of genetically conditioned 
variation in response to drugs (pharmacogenomics) 
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and unorthodox environmental effects (epigenetics). 
Every day the genome of a given cell receives one 
million lesions which should be repaired. Defects in 
repair mechanisms can lead to diseases, one impor-
tant category of them being neurological disorders. 
The association between intronic inversions which 
lead to severe hemophilia A and the prevalence of 
Factor VIII inhibitors in these patients was also 
considered using information obtained by the Porto 
Alegre group and those of colleagues living in other 
cities. The fi nal message emphasizes the need for an 
evolutionary approach to fully understand patholo-
gic processes and their management. Rev Arg An-
trop Biol 11(1):05-14, 2009.
1A similar text written in Portuguese was submitted 
elsewhere (Salzano, 2009).
WHAT IS GENOMIC MEDICINE?
Medicine is the art and science which 
aims to cure or alleviate symptoms of di-
sease. Genomics is the scientifi c study of 
the totality of the genetic material of a spe-
cies. Genomic medicine, therefore, would 
be the interaction between these two fi elds 
of knowledge. The progress which is occu-
rring in the areas of molecular biology and 
bioinformatics can be only characterized as 
phenomenal, infl uencing all the biological 
sciences and with a direct refl ex in medi-
cine. The completion of the total sequence 
of the human genome, which occurred in 
2003, can be viewed as merely a fi rst step 
for the understanding of normal and patho-
logical processes occurring in our bodies.
Different levels of study can be identi-
fi ed in genomic medicine (Table 1). DNA 
(deoxyribonucleic acid) gives the infor-
mation from which a whole sequence of 
events will form the basic substances of a 
living being (proteins, lipids, carbohydra-
tes) which will interact in a complex and 
integrated way through metabolic networ-
ks to (form) make the fi nal product (pheno-
me or phenotype) of an individual.
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WHAT IS DARWINIAN MEDICINE?
Charles Darwin (1809-1882) was the 
scholar who placed evolution theory in 
a solid scientifi c background especially 
through his masterful “The Origin of Spe-
cies” (Darwin, 1859). Presently the evolu-
tionary process is conceived as being basi-
cally determined, as Darwin postulated, by 
natural selection. The latter can be simply 
defi ned as the survival of the fi ttest and the 
elimination of the less adapted. Natural se-
lection acts through two main components, 
viability and fertility (it is necessary to sur-
vive and reproduce in an adequate way). 
Of course, other factors can infl uence evo-
lutionary events. Structural restrictions 
exist, based in the histories of individuals 
or species, and these histories can condi-
tion the action of random factors, as the ac-
cidental elimination of favorable variants 
or the fi xation of neutral characteristics in 
small populations.
Darwinian medicine is the area of 
knowledge which deals with the appli-
cation of evolutionary principles to the 
understanding of health and disease. The 
term can be traced back to an article pu-
blished in the Quartely Review of Biology 
in 1991 by Randolph M. Nesse and George 
C. Williams (Nesse and Williams, 1997) 
and some of the questions asked are listed 
on Table 2. The answers to these questions 
undoubtedly are not easy, but they are be-
ing actively searched in researches perfor-
med all over the world; and Stearns and 
Koella (2008) recruited a selected group 
of specialists who indicated the state of the 
art at that time.
One of the most intriguing problems 
concerns mother-offspring evolutionary 
confl icts. A fraction of women with gesta-
tional hypertension develops preeclamp-
sia, a condition that involves proteinuria 
caused by endothelial dysfunction, as well 
as necrosis and hemorrhage in several ma-
Levels Characterization
Genome The complete set of the genetic material (DNA) of a species.
Transcriptome The totality of the initial product of DNA replication (mRNA).
Proteome All the proteins of an organism.
Lipidome The total lipid molecules of an organism.
Glycome The set of all carbohydrates of an organism.
Metabolome Complete set of metabolites (molecules of low molecular weight) of an
organism.
Secretome The population of gene products secreted by a cell or tissue.
Interactome The totality of the interactions occurring in the functioning of an
organism.
Regulome The entire set of functional regulatory networks.
Phenome The anatomical and physiological characteristics of an organism.
Epigenome All the external factors which can influence, more or less permanently,
the genetic material of an organism.
TABLE 1. Levels of study in genomic medicine
Source: King and Stansfi eld (2002); Pena (2004); Koonin and Wolf (2008).
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TABLE 2. Questions considered by darwinian medicine
1. How does natural selection work? Why do our bodies show their present characteristics? 
What restrictions and adjustments occurred during their evolution?
2. Why do diseases still exist?
3. If lizards can regenerate their lost tails, why is it not possible to regenerate a lost fi nger 
in humans?
4. If the control of cell division in multicellular organisms was developed at about 600 
million years ago, why in certain circumstances this control is lost, with the onset of 
carcinogenic processes?
5. Why do we have pain and fever?
6. Why do we age?
Source: Nesse (2004).
ternal tissues. In these cases placenta re-
leases factors which may cause maternal 
endothelium dysfunction. If the problem 
develops before the completion of the ges-
tational period a dilemma arises: the longer 
gestation is maintained, the less are the in-
fant risks, but the greater the maternal mor-
bidity and mortality risks. There are two 
explanations for the pathology; the fi rst is 
that it arises as a side effect of abnormal 
physiological processes that would be mal-
adaptative for mother and fetus as well. But 
the alternative is that preeclampsia is mal-
adaptive to the mother but adaptative to the 
fetus. The function of the placental factors 
responsible for the maternal endothelial 
dysfunction would be to increase the blood 
fl ow to the placenta, what would be im-
portant for fetuses with growth restriction. 
The evolutionary perspective does not im-
mediately suggests better treatment for the 
disease, but can encourage new hypotheses 
about its proximate causes (Haig, 2008).
SYSTEMS BIOLOGY
Systems biology attempts to achieve 
an integrated understanding of life forms 
at multiple levels. Characteristically, it in-
volves large-scale measurement, such as a 
whole cell or even an entire multicellular 
organism. The development of molecular 
and bioinformatic tools led to the possibi-
lity of investigating the whole set of enti-
ties of a certain class found in an organism, 
tissue, organ or cell. Complex phenomena 
as those considered by these approaches 
can be analysed in the form of a network, 
composed by nodes and the connections 
between them, the edges. Evidence has 
been obtained that a gene’s centrality in 
a network could constrain its rate of evo-
lution. But the amount of variability of a 
given genetic region seems to depend on 
several other variables, such as the levels 
of expression of its units, and the degree 
of their dispensability. The most important 
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genes would be those that are highly ex-
pressed, interact with many other proteins, 
have multiple paralogs, show strong fi tness 
reduction upon knockout, are rarely lost 
during evolution, and evolve slowly at the 
sequence level (Koonin and Wolf, 2008).
This scenario emphasizes the status 
quo. But Camps et al. (2007) contended 
that a convergence of directed evolution, 
population genetics, genomics analy-
sis, and experimental adaptation studies 
(experiments) indicated that positive se-
lection (the favoring of the new-variants 
that increase the fi tness of an organism) 
is a fundamental driver of evolution. The 
positively selected mutations are of two 
kinds, those that directly affect enzyma-
tic functions, and compensatory variants, 
which suppress pleiotropic, slightly dele-
terious effects of the former.
Duarte et al. (2007) have made a glo-
bal reconstruction of the human metabolic 
network based on genomic and bibliomic 
information. They identifi ed 1,865 genes 
which were associated with 3,623 enzy-
mes and 3,673 reactions, making possible: 
(a) to identify where important gaps of in-
formation occur for the global knowledge 
of these processes; (b) the formulation of 
in silico models; (c) evaluation of the im-
plications of intracellular compartmentali-
zation; and (d) clues for the potential use 
of correlated reaction sets for drug target 
identifi cation.
In a similar approach, Goh et al. (2007) 
devised what they called the human disea-
se network, examining the relationships 
among the genetic disorders. They verifi ed 
that of 1,284 conditions 867 had at least 
one link to other diseases, and 516 of them 
formed a giant component. On the other 
hand, 1,377 of 1,777 disease genes were 
connected with others of the same type, 
and 903 clustered in a single block. The 
number of genes associated with a given 
disorder could be high: 41 for deafness, 37 
for leukemia, and 34 for colon cancer.
HOST-PATHOGEN COEVOLUTION
Some of the most elegant examples of 
ongoing evolution are provided by host-
parasite coevolutionary relationships. In its 
most strict sense we can only characterize 
a situation as coevolutionary when one of 
the species in interaction varies in genetic 
composition in response to a genetic varia-
tion in the other(s). Many factors are invol-
ved in the host-pathogen relationships. For 
both organisms size, rate of reproduction, 
life histories, and genetic variability mat-
ters. Interactions between the host immune 
system and the pathogen virulence are of 
utmost importance, as well as the type of 
the target organs and parasite density in 
them, the occurrence of single or multiple 
agents of disease, and in the latter case the 
competition between them. Biotic or abio-
tic vectors provide additional variables that 
should be taken into consideration. This 
multitude of sources of variation, of cour-
se, make quantitative analytic treatments 
diffi cult. But for recent analyses about the 
evolution and expression of virulence see 
Ebert and Bull (2008) and Koella and Tur-
ner (2008).
Domínguez-Bello et al. (2008) have in-
vestigated the multilocus sequences from 
seven housekeeping genes of Helicobater 
pylori, a human gastric indigenous bacteria 
which may cause gastric cancer and peptic 
ulcer disease. The study involved material 
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from Africans, Europeans, Asians, Ame-
rindians, and South American Mestizos. 
Strains that had been cultured from Afri-
cans, Europeans, and Asians were all cha-
racteristic of people from these continents 
only. However, Amerindians and Mestizos 
carried mixed strains: hspAmerind and 
hpEurope were found in Amerindians, and 
hpEurope and hpAfrica1 in Mestizos. A 
comparison was made between the genetic 
diversity of these strains with those of the 
mtDNA of 1,148 people from the same or 
nearby populations. The least genetically 
diverse H. pylori strains were hspAme-
rind, isolated from the most homogeneous 
human populations. On the other hand, 
hpEurope, highly diverse, seems to be ex-
panding its host range. Coevolutionary re-
lationships are clear.
Another pathogen, human herpesvi-
rus type 8 (HHV-8), also called Kaposi 
sarcoma-associated herpesvirus, is the 
etiological agent of all forms of this sar-
coma, primary effusion lymphoma, and 
certain lymphoproliferative disorders. Not 
all affected, however, develop these con-
ditions, indicating virus-host synergism. 
Antibody prevalences against HHV-8 
are low in western populations (less than 
5%), they are higher in Africa, but the hig-
hest reported were found in Amerindians. 
Souza et al. (2009) recently obtained data 
from 760 individuals from 11 Brazilian, 
Bolivian and Paraguayan Amerindian po-
pulations, comparing them with those of 
2,479 subjects from 26 indigenous groups 
of Brazil, French Guiana, and Ecuador. 
The range of frequencies was surprisingly 
high (0%-83%); factors which may be in-
fl uencing this variability are: (a) Host and 
virus genotypes; so far only HHV-8 sub-
type E was found in Amerindians, but the 
number of studies considering this point is 
small; or (b) Environmental variables such 
as time which elapsed from the virus fi rst 
introduction into the population, preferred 
routes of transmission, human population 
density and mobility, as well as behavio-
ral characteristics favoring or preventing 
transmission.
Mycobacterium tuberculosis has been 
a human pathogen for millennia. Molecu-
lar studies indicated that the M. tubercu-
losis complex (including also M. canettii, 
M. microti, M. bovis, and M. africanus) 
should have had an African origin may be 
2.5 million years ago. The American pa-
thogen was identifi ed as member of this 
complex, and should have been present in 
the prehistoric peopling of the continent. 
But osseous evidence for tuberculosis was 
only observed in remains of approximately 
300 AD (Wilbur et al., 2008).
Infection with M. tuberculosis, an in-
tracellular pathogen, results in disease in 
only 5%-10% of those exposed; the others 
remain unaffected. Most of them develop 
a delayed-type hypersensitivity response 
two to four weeks after infection, manifes-
ted by a positive response (skin induration) 
to intradermal injection with purifi ed pro-
tein derivative (PPD) from the bacteria, the 
Tuberculin Skin Test (TST).
The Aché of eastern Paraguay had ne-
ver seen tuberculosis before recent contact 
with other groups and had no word for the 
disease in their language. A longitudinal 
study since the inception of their exposure 
to the pathogen verifi ed that in fewer than 
15 years 18% of the population had been 
diagnosed with active tuberculosis (Hurta-
do et al., 2004).
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The lack of skin induration after the 
PPD intradermal injection is defi ned as 
anergy and may occur due to variability in 
a group of small proteins, cytokines, invol-
ved primarily in communication between 
cells of the immune system. The Xavante 
Amerindians of central Brazil are being 
studied by our group for half a century now 
(review in Coimbra et al., 2002) and show 
a high rate of anergy even after newborn 
BCG vaccination. To investigate this phe-
nomenon, Zembrzuski et al. (2009) have 
performed a detailed investigation of 19 
polymorphisms in 15 genes related to the 
immune response from almost all indivi-
duals (481) of the Etéñitépa village. Aner-
gy was observed in 69% of the subjects, 
and polymorphisms in four genes (SP110, 
PTPN22, IL12RB1, and IL6) were absent 
or showed very little variability, in contrast 
with fi ndings in other ethnic groups. Three 
others (IFNG, IL4, and IL10) were signifi -
cantly associated with response to TST. In 
tribal groups such as the Xavante exposure 
to a variety of infections and trauma, as-
sociated with specifi c genetic factors, may 
disturb the T-helper 1 and T-helper 2 ba-
lance, leading to increased immunological 
susceptibility (Hurtado et al., 2004). The 
public health importance of studies like the 
one reviewed here for the health of com-
munities living at this level of socioecono-
mic development is obvious.
SEARCHING FOR THE ETIOLOGY OF 
GENETIC DISEASES
A large number of common diseases 
has a multifactorial etiology, associated 
to genetic and environmental characteris-
tics. Since natural selection has acted for 
thousands of years in our genome, genetic 
risk factors should be related to low fre-
quency alleles. Genome analyses for the 
identifi cation of these factors involve non-
trivial costs, but technological progress is 
making possible the testing of nothing less 
than 500 thousand SNPs (single nucleotide 
polymorphisms) in a single experiment! 
As a consequence, important progress oc-
curred in the understanding of the etiology 
of complex diseases, like type 2 diabetes 
mellitus (of late onset), myocardial infarc-
tion, prostate cancer, and obesity (Ropers, 
2007). 
On the other hand, only about two 
thousand of the 25 thousand protein-co-
ding human genes and practically none of 
the non-codifying genes were related to 
diseases, and causal mutations are known 
for only 3,345 gene-mapped genetic illnes-
ses. Since familial recurrence not always 
occurs in genetic diseases (example: auto-
somal dominant severe diseases of early 
onset), only a fraction of them is known. 
In the mouse, where knockout experiments 
can be done, only 3% to 4% of the muta-
tions do not show a phenotypic manifesta-
tion (Ropers, 2007).
A special class of diseases are those due 
to genetic changes in mitochondrial DNA 
(mtDNA). The organism which gave ori-
gin to our mitchondria invaded an eukar-
yotic cell two to three billion years ago. In 
the course of evolution many of their genes 
(about 1,500) were transferred to nuclear 
DNA, only 37 remaining in the organelle. 
These genes are basically related to oxida-
tive phosphorilation, transforming diet ca-
lories in usable energy and secondarily ge-
nerating toxic oxygen reactive substances. 
Our hunter-gatherer ancestrals needed high 
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doses of energy; mutations that would in-
crease such doses would be favored at that 
time. Presently, however, with the control 
of environmental stimuli and high-caloric 
diets, such mutations turned to be harmful. 
The association between mtDNA muta-
tions and diseases involve clinical manifes-
tations which affect the brain, heart, skele-
tal muscle, kidney, and endocrine system, 
the same tissues that are affected by aging. 
Specifi c symptoms related to these muta-
tions are blindness, deafness, locomotion 
problems, dementia, cardiovascular disea-
se, muscular weakness, renal dysfunction, 
and diabetes (Wallace, 2005).
PHARMACOGENOMICS
This area of knowledge deals with ge-
netically conditioned variation in response 
to drugs. In the beginning the emphasis 
was placed in monogenic characteristics 
(pharmacogenetics). With the possibility 
of studying many genes simultaneously we 
are presently in the pharmacogenomics era 
(Hutz and Fiegenbaum, 2004).
The action of drugs can be infl uenced 
in different ways: (a) in its metabolization; 
(b) in membrane transport; (c) in target 
genes for drug action (for instance, recep-
tors). Drug metabolism generally occurs in 
two steps: phase 1 involves the introduc-
tion of small polar groups which increase 
aqueous solution solubility. At this stage 
the main genes involved are those which 
act in the P450 monooxygenase cytochro-
me superfamily (CYP450). Phase 2, on 
the other hand, includes the conjugation 
with acetate, inorganic sulphate, sugars or 
amino acids. The respective genes act on 
different series of enzymatic superfamilies 
(example: genes which act on glutathion S-
transferase).
MDR-1 (multidrug resistance gene) is 
one of the most studied among the ABC 
family of transporters (ATP-binding cas-
sete) and codifi es a membrane transmitter, 
P glycoprotein, which is very important 
for substrate availability; and at least 15 
MDR-1 polymorphic SNPs were detec-
ted. As for genes that could be targets for 
drugs, ECA’s variability could be impor-
tant in the response to inhibitors of the 
angiotensin conversion enzyme (Hutz and 
Fiegenbaum, 2004). The fi nal objective of 
these studies is individualized therapy; the 
drug’s dose would be adjusted to each per-
son in particular.
EPIGENETICS
The term refers to the study of the 
mechanisms by which genes lead to phe-
notypic effects. Cell clones could inherit 
phenotypic changes which are not due to 
nucleotide variations. DNA- linking pro-
teins codifi ed by regulatory genes some-
times produce epigenetic changes which 
could be preserved during the mitotic divi-
sions in somatic tissues. Generally, howe-
ver, meiosis erases these marks, and there-
fore the species ontogenetic program starts 
again in each generation. In multicellular 
organisms, therefore, these epigenetic pro-
cesses are especially important with rela-
tion to somatic mutations.
Gene expression is intimately connec-
ted to the addition of methyl groups to spe-
cifi c sites of the DNA molecule. Their ab-
sence is associated with transcription, their 
presence with gene silencing. Different 
degrees of DNA methylation in sperma-
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togenesis or oogenesis lead to differential 
expression of symptoms in certain disea-
ses, whether the transmission occurs via 
paternal or maternal inheritance (the phe-
nomenon called genomic imprinting). One 
of the classical examples is the 15q11-q13 
deletion, which when transmitted by the 
father leads to Prader-Willi syndrome, and 
when transmitted by the mother to the quite 
different Angelman syndrome. This effect 
is due to a center of genomic imprinting 
located in this region. It should be noted, 
however, that there are other causes for 
these two syndromes. Another heteroge-
neous condition, autism (characterized by 
the patient’s detachment from the external 
world and interpersonal relationships) can 
also have as one of its causes epigenetic 
phenomena (Beaudet, 2008).
DNA REPAIR AND NEUROLOGIC 
DYSFUNCTION
DNA damage is one determinant of cell 
dysfunction and death, carcinogenesis, and 
the aging process. Every day the genome 
of a given cell receives one million lesions! 
If these lesions are not repaired, mutations 
of several types, gene expression distur-
bances, or the formation of detrimental 
proteins may occur.
To cope with these problems cells are 
equipped with a large number of repair en-
zymes and pathways. Defects in them may 
lead to apoptosis (death) or cell transfor-
mation; and recently special attention was 
given as how these processes are refl ected 
in neurological diseases.
DNA damage sources can be endoge-
nous, caused by products or subproducts 
of the cell metabolism (for instance reac-
tive oxygen species, chelating agents and 
aldehydes); or exogenous, determined by 
physical (example: ionizing radiation) or 
chemical (heavy metals derived from polu-
tion, or afl atoxin, found in the food) agents 
which occur in the environment.
Examples of neurodegenerative disea-
ses due to DNA repair defects are certain 
types of ataxias (loss of body movement 
coordination) and xeroderma pigmentosum 
(a dermatologic affection). The pronounced 
sensibility of non-dividing neuronal cells 
to DNA damage can be explained by: (a) 
their reliance on replication-independent 
repair pathways for lesion removal; and (b) 
their high metabolic requirements with the 
associated oxidative burden (Kulkarni and 
Wilson, 2008).
SEVERE HEMOPHILIA A AND INTRO-
NIC INVERSIONS
Hemophilia A is a hemorrhagic disea-
se caused by a wide variety of changes 
in the Factor VIII coagulation gene. This 
gene is located in chromosome X’s long 
arm (Xq28) and is extremely complex. Its 
size totals 186 thousand base pairs, with 26 
exons (codifying units). The latter, howe-
ver, constitute just 5% of the gene, the re-
maining being formed by introns (regions 
situated between the exons).
Frequent causes of severe hemophilia A 
are two inversions which occur in introns 
22 and 1 of the gene. Studies performed by 
our group (Leiria et al., 2009) verifi ed, in 
107 patients of this type, prevalences res-
pectively of 46% for inv. 22 and 3% for 
inv. 1. Comparisons with series involving 
3,871 severe hemophiliacs in 15 countries 
showed an extreme homogeneity (for inv. 
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22, 40-49% in 14 of the 21 series with at 
least 31 patients tested, distributed by 13 
nations).
In contrast with these fi ndings, the pre-
valence of Factor VIII inhibitors, one of 
the main therapeutic problems for these 
individuals, showed ample heterogeneity 
among inv. 22 carriers (5-51% in seven 
countries, 1,482 patients). The highest va-
lue was found in our series. This variabili-
ty is due to many factors. Besides inv. 22, 
the type of Factor VIII that these patients 
receive, von Willebrand factor, which 
acts as an immuno-coadjuvant, as well as 
other characteristics of their immune sys-
tem, should also be important. Our group 
is starting studies in these latter characte-
ristics, to better analyse the causes of this 
process.
FINAL MESSAGE
We are currently in the post-genomic 
era, in which DNA structural variation is 
related to a wide spectrum of phenomena 
that are manifested at the functional level. 
The search is for a synthetic vision, that 
could relate these different phenomena 
among themselves. Pathological processes 
can only be understood through an appro-
ach which transcends immediate facts, 
looking for an interpretation in the wide 
context of organic evolution. It is through 
this investigation that we eventually could 
establish in an appropriate way our posi-
tion in the universe.
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